On Aug. 9, 2020, Intravacc announced that it had been awarded a contract with base and options that may total US$9.4 million from the US National Institute of Allergy and Infectious Diseases (NIAID), for the development of a prophylactic vaccine against enterovirus D68 (EV D68).

EV D68 is a respiratory virus that can cause childhood paralysis, Acute Flaccid Myelitis (AFM). Intravacc will develop an inactivated EV D68 vaccine, based on Intravaccﾒs proprietary Vero cell technology, from early product selection through to Phase I clinical testing.